Efficacy and safety of tenofovir alafenamide fumarate in nucleoside analogue treatment-naïve patients with chronic hepatitis B

Abstract We report two treatment-naïve cases, a 26-year-old female patient and a 59-year-old male patient who were followed up for chronic hepatitis B (CHB) at the Department of Infectious Diseases and Clinical Microbiology. A partial response subsequent to 12 months of Tenofovir Disoproksil (TDF) monotherapy presumably due to an antiviral-drug resistance was noted. A sustained viral response with TDF (245 mg) or Tenofovir Alafenamide (TAF, 25 mg) + Entecavir (ETV, 1 mg) combination therapy was observed after failure with TDF monotherapy. A combination therapy with TDF (245 mg) or TAF (25 mg) +ETV (1 mg) is efficacious in naïve patients with a partial response to TDF monotherapy. Keywords: Chronic hepatitis B, Tenofovir, partial response, Entecavir, combination therapy

Download Full-text

Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients

European Journal of Gastroenterology & Hepatology ◽

10.1097/meg.0b013e3283511287 ◽

2012 ◽

Vol 24 (5) ◽

pp. 535-542 ◽

Cited By ~ 22

Author(s):

María Buti ◽

Rosa Maria Morillas ◽

Martín Prieto ◽

Moisés Diago ◽

Juan Pérez ◽

...

Keyword(s):

Chronic Hepatitis ◽

Clinical Practice ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Efficacy And Safety ◽

Treatment Naïve

Download Full-text

A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96

Journal of Hepatology ◽

10.1016/s0168-8278(17)30313-6 ◽

2017 ◽

Vol 66 (1) ◽

pp. S25-S26 ◽

Cited By ~ 8

Author(s):

M. Brunetto ◽

Y.S. Lim ◽

E. Gane ◽

W.K. Seto ◽

M. Osipenko ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Tenofovir Disoproxil Fumarate ◽

Efficacy And Safety ◽

Phase 3 ◽

Tenofovir Alafenamide ◽

Negative Chronic Hepatitis

Download Full-text

“COMPARATIVE EFFICACY OF ENTECAVIR AND TENOFOVIR ALAFENAMIDE IN TREATMENT OF CHRONIC HEPATITIS-B ”

10.36106/ijsr/2121073 ◽

2021 ◽

pp. 14-16

Author(s):

Navneet Kumar Dubey ◽

Ganesh Narayan Jha ◽

Debarshi Jana

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

P Value ◽

Comparative Efficacy ◽

B Virus ◽

Treatment Naïve ◽

Medical Intensive Care ◽

Tenofovir Alafenamide ◽

Patient Department

Aims:The Aim of study is to compare the efcacy of entecavir with tenofovir alafenamide in treatment of Chronic Hepatitis B patients. Materials and methods: It is a prospective cohort study to compare efcacy of ENTECAVIR and TAF in treatment of Chronic Hepatitis B. Study location was Out Patient Department(OPD), In Patient Department(IPD) and Medical Intensive care unit (MICU) of Dept. of Medicine of DMCH, Laheriasarai. Study duration was 12 months and total 50 individual was in this study. Result: 12% patients of Entecavir and 16% patients of TAF group were presented with HTN; while DM was observed in 4% patients of Entecavir and 8% patients of TAF group. Regarding co-morbidities we found no signicant difference between two groups (p value = >0.05). Hepatitis B virus DNAin the HBeAg positive group was approximately 2 log10 IU/mLhigher than in the HBeAg-negative group. Conclusion: Treatment with antiviral therapy, ETV or TAF, showed potent antiviral activity against HBV and the efcacy of both drugs was comparable.TAF and ETVshowed comparable efcacy and safety in treatment-naïve CHB patients.

Download Full-text